UCB SA (UCB.BR)
EUR 187.45
(0.83%)
EUR 187.45
(0.83%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.87 Billion EUR | 13.4% |
| 2022 | 2.53 Billion EUR | 28.77% |
| 2021 | 1.97 Billion EUR | -12.05% |
| 2020 | 2.24 Billion EUR | 145.19% |
| 2019 | 914 Million EUR | -28.98% |
| 2018 | 1.28 Billion EUR | -15.94% |
| 2017 | 1.53 Billion EUR | -3.77% |
| 2016 | 1.59 Billion EUR | -3.58% |
| 2015 | 1.65 Billion EUR | -5.06% |
| 2014 | 1.73 Billion EUR | -13.75% |
| 2013 | 2.01 Billion EUR | 6.61% |
| 2012 | 1.89 Billion EUR | 6.66% |
| 2011 | 1.77 Billion EUR | 0.8% |
| 2010 | 1.75 Billion EUR | 4.83% |
| 2009 | 1.67 Billion EUR | -15.98% |
| 2008 | 1.99 Billion EUR | 4.72% |
| 2007 | 1.9 Billion EUR | -37.49% |
| 2006 | 3.04 Billion EUR | 197.75% |
| 2005 | 1.02 Billion EUR | 314.55% |
| 2004 | 247.01 Million EUR | -19.74% |
| 2003 | 307.78 Million EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.84 Billion EUR | 0.0% |
| 2023 FY | 2.87 Billion EUR | 13.4% |
| 2023 Q2 | 2.51 Billion EUR | 0.0% |
| 2023 Q4 | 2.87 Billion EUR | 0.0% |
| 2022 FY | 2.53 Billion EUR | 28.77% |
| 2022 Q2 | 2.77 Billion EUR | 0.0% |
| 2022 Q4 | 2.53 Billion EUR | 0.0% |
| 2021 Q2 | 1.93 Billion EUR | 0.0% |
| 2021 Q4 | 1.97 Billion EUR | 0.0% |
| 2021 FY | 1.97 Billion EUR | -12.05% |
| 2020 Q4 | 2.24 Billion EUR | 0.0% |
| 2020 Q2 | 2.38 Billion EUR | 0.0% |
| 2020 FY | 2.24 Billion EUR | 145.19% |
| 2019 Q4 | 914 Million EUR | 0.0% |
| 2019 FY | 914 Million EUR | -28.98% |
| 2019 Q2 | 928 Million EUR | 0.0% |
| 2018 Q4 | 1.28 Billion EUR | 0.0% |
| 2018 FY | 1.28 Billion EUR | -15.94% |
| 2018 Q2 | 1.37 Billion EUR | 0.0% |
| 2017 FY | 1.53 Billion EUR | -3.77% |
| 2017 Q2 | 1.54 Billion EUR | 0.0% |
| 2017 Q4 | 1.53 Billion EUR | 0.0% |
| 2016 Q4 | 1.59 Billion EUR | 0.0% |
| 2016 FY | 1.59 Billion EUR | -3.58% |
| 2016 Q2 | 1.59 Billion EUR | 0.0% |
| 2015 Q4 | 1.65 Billion EUR | 0.0% |
| 2015 Q2 | 2.07 Billion EUR | 0.0% |
| 2015 FY | 1.65 Billion EUR | -5.06% |
| 2014 Q2 | 1.64 Billion EUR | 0.0% |
| 2014 FY | 1.73 Billion EUR | -13.75% |
| 2014 Q4 | 1.73 Billion EUR | 0.0% |
| 2013 Q4 | 2.02 Billion EUR | 0.0% |
| 2013 FY | 2.01 Billion EUR | 6.61% |
| 2013 Q2 | 2.23 Billion EUR | 0.0% |
| 2012 Q2 | 1.87 Billion EUR | 0.0% |
| 2012 FY | 1.89 Billion EUR | 6.66% |
| 2012 Q4 | 1.89 Billion EUR | 0.0% |
| 2011 Q4 | 1.77 Billion EUR | 0.0% |
| 2011 Q2 | 1.72 Billion EUR | 0.0% |
| 2011 FY | 1.77 Billion EUR | 0.8% |
| 2010 FY | 1.75 Billion EUR | 4.83% |
| 2010 Q4 | 1.75 Billion EUR | 0.0% |
| 2010 Q2 | 1.72 Billion EUR | 0.0% |
| 2009 Q4 | 1.67 Billion EUR | 0.0% |
| 2009 FY | 1.67 Billion EUR | -15.98% |
| 2008 FY | 1.99 Billion EUR | 4.72% |
| 2007 FY | 1.9 Billion EUR | -37.49% |
| 2006 FY | 3.04 Billion EUR | 197.75% |
| 2005 FY | 1.02 Billion EUR | 314.55% |
| 2004 FY | 247.01 Million EUR | -19.74% |
| 2003 FY | 307.78 Million EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -261298.728% |
| ABIVAX Société Anonyme | 44.69 Million EUR | -6338.911% |
| Adocia SA | 4.54 Million EUR | -63292.07% |
| Aelis Farma SA | 2.04 Million EUR | -140427.344% |
| Biophytis S.A. | 3.11 Million EUR | -92410.447% |
| Advicenne S.A. | 15.89 Million EUR | -18005.184% |
| genOway Société anonyme | 5.51 Million EUR | -52044.284% |
| IntegraGen SA | 642.28 Thousand EUR | -447991.175% |
| Medesis Pharma S.A. | 1.2 Million EUR | -239733.333% |
| Neovacs S.A. | 650 Thousand EUR | -442669.231% |
| NFL Biosciences SA | 39.2 Thousand EUR | -7341174.902% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -65962.069% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -146712.091% |
| Sensorion SA | 1.24 Million EUR | -231826.383% |
| Theranexus Société Anonyme | 2.46 Million EUR | -116857.733% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -73732.735% |
| TheraVet SA | 1 Million EUR | -287527.711% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -41573.907% |
| argenx SE | 15.35 Million EUR | -18644.301% |
| BioSenic S.A. | 15.57 Million EUR | -18380.704% |
| Celyad Oncology SA | 902 Thousand EUR | -318968.736% |
| DBV Technologies S.A. | 4.52 Million USD | -63488.157% |
| Galapagos NV | 4.94 Million EUR | -58111.974% |
| Genfit S.A. | 62.25 Million EUR | -4523.07% |
| GeNeuro SA | 6.49 Million EUR | -44229.436% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -836527.907% |
| Innate Pharma S.A. | 30.6 Million EUR | -9303.078% |
| Inventiva S.A. | 25.61 Million EUR | -11135.166% |
| MaaT Pharma SA | 5.42 Million EUR | -52950.691% |
| MedinCell S.A. | 52.8 Million EUR | -5350.758% |
| Nanobiotix S.A. | 41.66 Million EUR | -6808.305% |
| Onward Medical N.V. | 16.3 Million EUR | -17549.945% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -83305.422% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -8005.216% |
| Oxurion NV | 117 Thousand EUR | -2459729.06% |
| Pharming Group N.V. | 123.65 Million EUR | -2227.401% |
| Poxel S.A. | 40.14 Million EUR | -7069.37% |
| GenSight Biologics S.A. | 1.04 Million EUR | -274518.321% |
| Transgene SA | 17 Thousand EUR | -16929311.765% |
| Financière de Tubize SA | - EUR | -Infinity% |
| Valneva SE | 132.76 Million EUR | -2067.691% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |